357 related articles for article (PubMed ID: 17001185)
21. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
22. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.
Dalle JH; Wall D; Theoret Y; Duval M; Shaw L; Larocque D; Taylor C; Gardiner J; Vachon MF; Champagne MA
Bone Marrow Transplant; 2003 Oct; 32(7):647-51. PubMed ID: 13130310
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
25. Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation.
Cho YH; Lim HA; Lee MH; Kim I; Lee JS; Park Sy; Kim BK; Yoon SS
Clin Transplant; 2007; 21(3):417-22. PubMed ID: 17488395
[TBL] [Abstract][Full Text] [Related]
27. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
[TBL] [Abstract][Full Text] [Related]
28. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
Ryu SG; Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Hur EH; Lee SH; Bae KS; Noh GJ; Lee MS; Yun SC; Han SB; Lee KH
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1095-105. PubMed ID: 17697972
[TBL] [Abstract][Full Text] [Related]
29. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
30. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
[TBL] [Abstract][Full Text] [Related]
32. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
33. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
Clopés A; Sureda A; Sierra J; Queraltó JM; Broto A; Farré R; Moreno E; Brunet S; Martino R; Mangues MA
Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
[TBL] [Abstract][Full Text] [Related]
34. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
35. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
[TBL] [Abstract][Full Text] [Related]
36. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.
Greystoke B; Bonanomi S; Carr TF; Gharib M; Khalid T; Coussons M; Jagani M; Naik P; Rao K; Goulden N; Amrolia P; Wynn RF; Veys PA
Br J Haematol; 2008 Jun; 142(2):257-62. PubMed ID: 18492115
[TBL] [Abstract][Full Text] [Related]
37. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
[TBL] [Abstract][Full Text] [Related]
38. Re: intravenous versus oral busulfan--perhaps not as different as suggested.
Slattery JT
Biol Blood Marrow Transplant; 2003 Apr; 9(4):282-4. PubMed ID: 12720221
[No Abstract] [Full Text] [Related]
39. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
[TBL] [Abstract][Full Text] [Related]
40. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
Copelan EA; Bechtel TP; Avalos BR; Elder PJ; Ezzone SA; Scholl MD; Penza SL
Bone Marrow Transplant; 2001 Jun; 27(11):1121-4. PubMed ID: 11551021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]